TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03006328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM
Description: Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
Study: NCT00497926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoietic Stem Cell Infusion
Description: Enriched Hematopoietic Stem Cell Infusion
Study: NCT01802411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL 266 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02663128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study: NCT04689113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incontinence Health Belief Development Program
Description: After the applied interventions, it is desired to develop kegel exercise behavior in women.
Study: NCT04285892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Description: CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house.
Study: NCT02977377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
Study: NCT03325413

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic inclusion of family members
Description: Systematic inclusion of family members/ reference person in the perioperative process

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic inclusion of family members
Description: Systematic inclusion of family members/ reference person in the perioperative process

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preoperative information
Description: Detailed preoperative information about delirium prevention and procedures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preoperative information
Description: Detailed preoperative information about delirium prevention and procedures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical and breathing exercises
Description: Preoperative execution of physical and breathing exercises if necessary

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical and breathing exercises
Description: Preoperative execution of physical and breathing exercises if necessary

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary supplements
Description: Dietary supplements if necessary

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary supplements
Description: Dietary supplements if necessary

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of long-term medication
Description: Avoidance of unsuitable drugs for elderly if possible

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of long-term medication
Description: Avoidance of unsuitable drugs for elderly if possible

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia whenever possible

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia whenever possible

Intervention type: OTHER
Group type: OTHER
Intervention: Personal aids
Description: Personal orientation aids until anesthesia induction

Intervention type: OTHER
Group type: OTHER
Intervention: Personal aids
Description: Personal orientation aids until anesthesia induction

Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature management
Description: Perioperative warming

Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature management
Description: Perioperative warming

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurmonitoring
Description: Using Bispectral index (BIS) to measure the depth of anesthesia

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurmonitoring
Description: Using Bispectral index (BIS) to measure the depth of anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pain catheter
Description: A pain catheter will be used as postoperative pain therapy if possible

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pain catheter
Description: A pain catheter will be used as postoperative pain therapy if possible
Study: NCT03930745

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal inserts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL-463
Description: TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
Study: NCT06341244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Stacking Technique
Description: To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
Study: NCT02670629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial reduction with overriding position
Description: The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed anatomic reduction
Description: The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
Study: NCT01175655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSC
Description: mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
Study: NCT03705754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carbon black suspension colonic tattoo injection
Description: Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
Study: NCT06650917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the experiment group were treated acupoint massage combined with ear point pressing beans
Description: Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday.
Study: NCT03265405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose prednisolone
Description: An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose prednisolone
Description: An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
Study: NCT03261557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + SST
Description: It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual.
Study: NCT06650917

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the control group were treated with acupoint massage
Description: Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage.
Study: NCT03261557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation, habits and healthy lifestyle
Description: Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual.
Study: NCT01343706

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediate release solid oral dosage (film-coated tablet)
Study: NCT02217657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool Smart Touch Catheter
Description: Physician informed to contact force

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool Smart Touch Catheter
Description: Physician informed to contact force
Study: NCT02392975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast MR
Description: Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
Study: NCT01343706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)
Study: NCT02392975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
Study: NCT02460861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsies of the prostatic fossa in Magdeburg
Description: intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
Study: NCT01343706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: solution for oral administration
Study: NCT03285477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment 1%
Description: The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
Study: NCT01692197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7070
Description: 400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein daily for 3 - 4 days with cytarabine.
Study: NCT01590641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
Study: NCT02120924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Study: NCT00969852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
Study: NCT04090944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position
Description: -The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position
Description: -The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
Study: NCT00829621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75 mmHg suction
Description: Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125 mmHg
Description: Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
Study: NCT01003418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
Description: Two doses; intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
Description: Two doses; intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Routine infant immunisation vaccine, three doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Routine infant immunisation vaccine, three doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Routine infant immunisation vaccine, three doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Routine infant immunisation vaccine, three doses administered intramuscularly
Study: NCT00175136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxim TKA
Description: Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
Study: NCT00578370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin 0.5% (Formulation 01B)
Description: Cutaneous emulsion 200µl once a day (26 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin 1.5% (Formulation 02B)
Description: Cutaneous emulsion 200µl once a day (26 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone
Description: Solution 200µl once a day (26 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% calcipotriol
Description: Solution 200µl once a day (26 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formulation 00B
Description: Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
Study: NCT04596072

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chinese traditional rehabilitation
Description: Chinese traditional rehabilitation including acupuncture and herbs